Roivant Sciences (NASDAQ:ROIV) Trading Down 2.5%

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) fell 2.5% during mid-day trading on Friday . The company traded as low as $7.89 and last traded at $7.90. 201,439 shares were traded during mid-day trading, a decline of 92% from the average session volume of 2,543,887 shares. The stock had previously closed at $8.10.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 14th. Citigroup raised their target price on shares of Roivant Sciences from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, January 5th. The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, January 19th. JPMorgan Chase & Co. raised their price target on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, February 13th. Finally, SVB Leerink raised their target price on shares of Roivant Sciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Roivant Sciences has a consensus rating of “Buy” and a consensus price target of $12.50.

Roivant Sciences Stock Performance

The company has a market cap of $6.11 billion, a PE ratio of -4.52 and a beta of 1.26. The firm’s fifty day moving average is $8.39 and its 200 day moving average is $6.01. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 0.26.

Insider Transactions at Roivant Sciences

In other news, Director Vivek Ramaswamy sold 4,000,000 shares of the business’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $7.95, for a total transaction of $31,800,000.00. Following the transaction, the director now owns 54,409,211 shares of the company’s stock, valued at approximately $432,553,227.45. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, COO Eric Venker sold 95,484 shares of the company’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $7.32, for a total transaction of $698,942.88. Following the sale, the chief operating officer now directly owns 753,466 shares in the company, valued at $5,515,371.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Vivek Ramaswamy sold 4,000,000 shares of the stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of $7.95, for a total transaction of $31,800,000.00. Following the completion of the transaction, the director now owns 54,409,211 shares in the company, valued at $432,553,227.45. The disclosure for this sale can be found here. Insiders sold 4,133,162 shares of company stock valued at $32,789,272 over the last 90 days. 13.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System grew its position in Roivant Sciences by 0.7% in the 3rd quarter. California State Teachers Retirement System now owns 238,961 shares of the company’s stock valued at $769,000 after buying an additional 1,703 shares during the last quarter. Pathstone Family Office LLC boosted its position in shares of Roivant Sciences by 6.1% during the 3rd quarter. Pathstone Family Office LLC now owns 38,488 shares of the company’s stock worth $124,000 after purchasing an additional 2,227 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Roivant Sciences by 25.4% during the 1st quarter. Hsbc Holdings PLC now owns 14,684 shares of the company’s stock worth $71,000 after buying an additional 2,978 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Roivant Sciences by 3.7% during the 4th quarter. Legal & General Group Plc now owns 101,495 shares of the company’s stock worth $811,000 after buying an additional 3,578 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Roivant Sciences by 5.7% during the 4th quarter. Arizona State Retirement System now owns 79,504 shares of the company’s stock worth $635,000 after buying an additional 4,276 shares during the last quarter. 52.66% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.